Research programme: myocardial perfusion imaging agents - Lantheus Medical Imaging

Drug Profile

Research programme: myocardial perfusion imaging agents - Lantheus Medical Imaging

Alternative Names: [18F]-RP1012

Latest Information Update: 13 Aug 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb Medical Imaging
  • Developer Lantheus Medical Imaging
  • Class Pyridazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Myocardial ischaemia

Most Recent Events

  • 13 Aug 2008 Preclinical development is ongoing in USA
  • 27 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Diagnostic Agents pharmacodynamics section
  • 20 Dec 2005 Preclinical trials in Diagnostic imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top